Introduction:

Candidemia is a clinical entity increasing in patients in intensive care unit, the inmuncompromised and multiple invasion makes them subject of fungal dissemination and increase in mortality. Use of scores to estimate the risk of developing candidemia has allowed start prophylactic antifungal azoles; however, the development of Candida albicans has not increased, generating uncertainty about the benefit that can have these measures initiated in early mortality.

Objectives:

To determine whether patients who received prophylactic any antifungal azole has impact on the development of Candida non-albicans in patients admitted to the intensive care unit.

Methods:

A retrospective, longitudinal, analytical study. Patients over 18 years enter the intensive care unit with sepsis. Determined that patients received prophylactic azoles and those who have developed Candida albicans and non-albicans.

Statistical analysis:

Statistical analysis was performed using Student T for comparison group and χ 2 for categorical variables. The results are expressed in average, ±, standard deviation and percentage. It is considered statistically significant if p ≤ 0.05, analysis using statistical system SPSS Statistics 21.

Results:

25 patients, 2-year period, age 72 ± 13 years (45-92), 15 men (60%), abdominal sepsis 56% (n = 14), APACHE II 14 ± 5 (5-29) and SOFA 6 ± 3. Culture without growth in 16 patients (64%), Candida albicans 4 (16%) and non albicans in 5 (20%).

Conclusions:

The incidence of Candida albicans in patients not receiving prophylaxis with fluconazole is low, with no increase in mortality, and we believe that the use of fluconazole as prophylactic management remains an appropriate measure in this group.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )